Myers D M, Hyland S, Paulini A, Melaragno A, Passias B J, Taylor B C
Department of Orthopaedic Surgery, OhioHealth, Columbus, United States.
Malays Orthop J. 2022 Jul;16(2):110-118. doi: 10.5704/MOJ.2207.014.
Knee dislocations (KD) have high rates of multi-ligamentous injury (MLI). Collateral ligaments rupture in 50-60% of KDs. Traditionally, collateral ligaments have undergone primary repair, though microscopic healing is not optimal. Artelon is a degradable, polyurethane urea bio-scaffold thought to decrease mechanical forces and promote healing, motion, and strength. Currently, little evidence exists regarding its indications or outcomes.
Thirty-two patients with KD and MLI undergoing collateral ligament repair at a level-I trauma centre between 2015-2020 were included. Patients age <18, with ipsilateral fractures or inadequate follow-up were excluded. The Artelon (AG) and primary ligamentous repair group (PR) each included 16 patients. Injury and perioperative variables were evaluated using SPSS® .
Thirty-two KDs were included in 32 patients, with 60% anterior. There were no significant differences between the two cohorts demographically or with regards to the type or severity of injury sustained. Meniscal pathology was addressed in 14 patients in both groups. Thirty-eight percent of all patients lacked >15° of knee flexion. Only one gross failure occurred, in the AG. No differences were noted in infection or re-operation. Lysholm Knee Scale and Tegner Activity Scale were not significantly different, although Tegner scores in both cohorts decreased from pre-injury scores.
In summary, Artelon appears to be safe without increasing risk for hypersensitivity or infection when used for collateral ligament augmentation. Additionally, Artelon appeared to be non-inferior and statistically equivalent to primary repair in this setting and may have promise with use in certain types of knee dislocations.
膝关节脱位(KD)常伴有多韧带损伤(MLI)。50%-60%的KD伴有侧副韧带断裂。传统上,侧副韧带采用一期修复,但微观愈合效果并不理想。Artelon是一种可降解的聚氨酯脲生物支架,被认为可降低机械力并促进愈合、活动和力量恢复。目前,关于其适应证或疗效的证据较少。
纳入2015年至2020年期间在一级创伤中心接受侧副韧带修复的32例KD合并MLI患者。排除年龄<18岁、同侧骨折或随访不充分的患者。Artelon组(AG)和韧带一期修复组(PR)各有16例患者。使用SPSS®评估损伤和围手术期变量。
32例患者共纳入32例KD,其中60%为前脱位。两组在人口统计学特征、损伤类型或严重程度方面无显著差异。两组均有14例患者处理了半月板病变。所有患者中有38%膝关节屈曲度小于15°。仅AG组出现1例严重失败病例。在感染或再次手术方面未发现差异。Lysholm膝关节评分和Tegner活动评分无显著差异,尽管两组的Tegner评分均较伤前评分降低。
总之,Artelon用于增强侧副韧带时似乎是安全的,不会增加过敏或感染风险。此外,在这种情况下,Artelon似乎不劣于一期修复,且在统计学上等效,可能对某些类型的膝关节脱位有应用前景。